Variable | Value |
---|---|
Age (n = 121)* | 69.5 ± 0.7 |
NAAD | 56/83 (67.5%) |
Time of hormonal treatment (mon; n = 52)* | 9.3 ± 1.1 |
Gleason Score (n = 132)† | 6 (5 - 10) |
Pre-PSA (ng/mL)* | 9.5 ± 0.6 |
Unilateral disease | 65/117 (55.6%) |
IMRT Boost | 31/130 (23.9%) |
Tumor stage | |
T1c | 100/130 (76.9%) |
T2 | 5/130 (3.9%) |
T2a | 13/130 (10.0%) |
T2b | 4/130 (3.1%) |
T2c | 2/130 (1.5%) |
T3 | 3/130 (2.3%) |
T3a | 2/130 (1.5%) |
T3b | 1/130 (0.8%) |